BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1426662)

  • 1. Recent progress in immunopharmacology and therapeutic effects of polysaccharides.
    Chihara G
    Dev Biol Stand; 1992; 77():191-7. PubMed ID: 1426662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor and metastasis-inhibitory activities of lentinan as an immunomodulator: an overview.
    Chihara G; Hamuro J; Maeda YY; Shiio T; Suga T; Takasuka N; Sasaki T
    Cancer Detect Prev Suppl; 1987; 1():423-43. PubMed ID: 3319150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation and consideration of BRM-BRM and HDP (host defense potentiators)].
    Chihara G
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1588-96. PubMed ID: 3382231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of lentinan in advanced or recurrent cases of gastric, colorectal, and breast cancer].
    Taguchi T
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):387-93. PubMed ID: 6349538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis.
    Suga T; Shiio T; Maeda YY; Chihara G
    Cancer Res; 1984 Nov; 44(11):5132-7. PubMed ID: 6488173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.
    Nakano H; Namatame K; Nemoto H; Motohashi H; Nishiyama K; Kumada K
    Hepatogastroenterology; 1999; 46(28):2662-8. PubMed ID: 10522061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of lentinan in animal models.
    Chihara G
    Adv Exp Med Biol; 1983; 166():189-97. PubMed ID: 6606302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of lentinan administration of adrenalectomized rats and patients with breast cancer].
    Kosaka A; Wani T; Hattori Y; Yamashita A
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1474-81. PubMed ID: 6764117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Modulation of anticancer effects of immunochemotherapeutic agents in various nutritional environments].
    Akimoto M; Nishihira T; Mori S
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):827-33. PubMed ID: 3260467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of Madison 109 lung carcinoma and other murine tumors using lentinan.
    Rose WC; Reed FC; Siminoff P; Bradner WT
    Cancer Res; 1984 Apr; 44(4):1368-73. PubMed ID: 6704958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions].
    Akimoto M; Nishihira T; Kasai M
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1270-6. PubMed ID: 3729450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of phase III study of lentinan].
    Taguchi T; Furue H; Kimura T; Kondo T; Hattori T; Itoh I; Ogawa N
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):366-78. PubMed ID: 3918510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experimental studies on growth inhibition and regression of cancer metastases].
    Chihara G
    Gan To Kagaku Ryoho; 1985 Jun; 12(6):1196-209. PubMed ID: 4004287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and perspectives of immunomodulators of microbial origin.
    Chihara G; Maeda YY; Hamuro J
    Int J Tissue React; 1982; 4(3):207-25. PubMed ID: 6815071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined use of lentinan with X-ray therapy in an experimental mouse tumor system (Part 2). Combined effect on the MM102 syngeneic tumor].
    Shiio T; Ohishi K; Tsuchiya Y; Niitsu I; Hayashibara H; Yoshihama T; Moriyuki H
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):475-9. PubMed ID: 3348633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-cancer effects of BRMs associated with nutrition in cancer patients].
    Nishihira T; Akimoto M; Mori S
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1615-20. PubMed ID: 3382233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case report of advanced gastric cancer remarkably responding to mitomycin C, aclacinomycin A, SF-SP and lentinan combination therapy].
    Maekawa S; Saku M; Kinugasa T; Yoshida Y; Ikejiri K; Yakabe S
    Gan To Kagaku Ryoho; 1990 Jan; 17(1):137-40. PubMed ID: 2105085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody-dependent murine macrophage-mediated cytotoxicity against human tumors is stimulated by lentinan.
    Herlyn D; Kaneko Y; Powe J; Aoki T; Koprowski H
    Jpn J Cancer Res; 1985 Jan; 76(1):37-42. PubMed ID: 3918909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey.
    Taguchi T
    Cancer Detect Prev Suppl; 1987; 1():333-49. PubMed ID: 3121179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denaturation and renaturation of a beta-1,6;1,3-glucan, lentinan, associated with expression of T-cell-mediated responses.
    Maeda YY; Watanabe ST; Chihara C; Rokutanda M
    Cancer Res; 1988 Feb; 48(3):671-5. PubMed ID: 2446749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.